ATE363533T1 - Osteoprotegerin bindende proteine und rezeptoren - Google Patents
Osteoprotegerin bindende proteine und rezeptorenInfo
- Publication number
- ATE363533T1 ATE363533T1 AT98918244T AT98918244T ATE363533T1 AT E363533 T1 ATE363533 T1 AT E363533T1 AT 98918244 T AT98918244 T AT 98918244T AT 98918244 T AT98918244 T AT 98918244T AT E363533 T1 ATE363533 T1 AT E363533T1
- Authority
- AT
- Austria
- Prior art keywords
- fragments
- encoding
- sequence
- nucleic acid
- receptors
- Prior art date
Links
- 102000014914 Carrier Proteins Human genes 0.000 title abstract 2
- 108091008324 binding proteins Proteins 0.000 title abstract 2
- 102000008108 Osteoprotegerin Human genes 0.000 title 1
- 108010035042 Osteoprotegerin Proteins 0.000 title 1
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 title 1
- 102000005962 receptors Human genes 0.000 title 1
- 108020003175 receptors Proteins 0.000 title 1
- 239000012634 fragment Substances 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 208000020084 Bone disease Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 210000002997 osteoclast Anatomy 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/842,842 US5843678A (en) | 1997-04-16 | 1997-04-16 | Osteoprotegerin binding proteins |
US88085597A | 1997-06-23 | 1997-06-23 | |
US09/052,521 US6316408B1 (en) | 1997-04-16 | 1998-03-30 | Methods of use for osetoprotegerin binding protein receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE363533T1 true ATE363533T1 (de) | 2007-06-15 |
Family
ID=27368158
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT98918244T ATE363533T1 (de) | 1997-04-16 | 1998-04-15 | Osteoprotegerin bindende proteine und rezeptoren |
Country Status (28)
Country | Link |
---|---|
US (1) | US7923008B2 (de) |
EP (2) | EP1717315A3 (de) |
JP (2) | JP2001526532A (de) |
CN (1) | CN1264427A (de) |
AT (1) | ATE363533T1 (de) |
AU (4) | AU743257B2 (de) |
BG (1) | BG65242B1 (de) |
BR (1) | BR9808545A (de) |
CA (1) | CA2285746C (de) |
CZ (1) | CZ302262B6 (de) |
DE (1) | DE69837845T3 (de) |
DK (1) | DK0975754T4 (de) |
EA (1) | EA003636B1 (de) |
EE (1) | EE05496B1 (de) |
ES (1) | ES2284203T5 (de) |
HK (1) | HK1022330A1 (de) |
HU (1) | HU230547B1 (de) |
ID (1) | ID23855A (de) |
IL (1) | IL132304A0 (de) |
NO (1) | NO325175B1 (de) |
NZ (1) | NZ500253A (de) |
PL (1) | PL190092B1 (de) |
RO (1) | RO128635A2 (de) |
SI (1) | SI0975754T2 (de) |
SK (1) | SK288559B6 (de) |
TR (1) | TR199902512T2 (de) |
TW (1) | TW589376B (de) |
WO (1) | WO1998046751A1 (de) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL117175A (en) | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
EP1114864B9 (de) * | 1996-12-13 | 2013-05-08 | Schering Corporation | Oberflächenantigene aus Säugern |
US6271349B1 (en) | 1996-12-23 | 2001-08-07 | Immunex Corporation | Receptor activator of NF-κB |
JP4138013B2 (ja) | 1996-12-23 | 2008-08-20 | イミュネックス・コーポレーション | Tnfスーパーファミリーのメンバーであるnf−kappa bの受容体アクティベーターに対するリガンド |
AU2008200700C1 (en) * | 1997-04-15 | 2013-04-04 | Daiichi Sankyo Co., Ltd | Novel Protein and Process for Producing The Same |
HU229476B1 (en) * | 1997-04-15 | 2014-01-28 | Daiichi Sankyo Company | Antibodies against obm |
US6316408B1 (en) | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
ATE363533T1 (de) | 1997-04-16 | 2007-06-15 | Amgen Inc | Osteoprotegerin bindende proteine und rezeptoren |
EP1076699B1 (de) * | 1998-05-14 | 2008-10-29 | Immunex Corporation | Verfahren zur hemmung der wirkung der osteoklasten |
WO2001060397A1 (en) | 2000-02-16 | 2001-08-23 | Genentech, Inc. | Uses of agonists and antagonists to modulate activity of tnf-related molecules |
US20020106728A1 (en) * | 2000-06-20 | 2002-08-08 | Genentech, Inc. | NS4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders |
EP1541587A3 (de) * | 1998-09-15 | 2007-06-20 | Pharmexa A/S | Verfahren zur Hemmung der Wirkung von Osteoprotegerin-Ligand |
WO2000015807A1 (en) * | 1998-09-15 | 2000-03-23 | M & E Biotech A/S | Method for down-regulating osteoprotegerin ligand activity |
ES2422231T3 (es) | 1998-10-23 | 2013-09-09 | Kirin Amgen Inc | Péptidos miméticos de trombopoyetina diméricos que se unen al receptor MP1 y que tienen actividad trombopoyética |
NZ515990A (en) | 1999-06-28 | 2003-10-31 | Genentech Inc | Methods for making Apo-2 ligand using divalent metal ions |
PL207501B1 (pl) | 1999-08-17 | 2010-12-31 | Apotech R & D Sa | Zastosowanie polipeptydu BCMA oraz przeciwciała skierowanego przeciwko BCMA |
WO2001023559A1 (en) * | 1999-09-27 | 2001-04-05 | Eli Lilly And Company | Osteoclast differentiation factor regulatory region |
AUPQ314799A0 (en) * | 1999-09-29 | 1999-10-21 | University Of Western Australia, The | Bone cell factor |
DK2105449T3 (da) † | 2000-02-23 | 2019-10-07 | Amgen Inc | Antagonistiske selektive bindemidler af osteoprotegerinbindende protein |
US20030103978A1 (en) * | 2000-02-23 | 2003-06-05 | Amgen Inc. | Selective binding agents of osteoprotegerin binding protein |
US6600018B1 (en) | 2000-04-10 | 2003-07-29 | The United States Of America As Represented By The Department Of Health And Human Services | Secreted frizzled related protein, sFRP, fragments and methods of use thereof |
EP1272647B1 (de) | 2000-04-11 | 2014-11-12 | Genentech, Inc. | Multivalente antikörper und deren verwendung |
DK1303293T3 (da) | 2000-07-27 | 2009-03-30 | Genentech Inc | Sekventiel indgivelse af CPT-11 og APO-2L-polypeptid |
AU2001286586A1 (en) * | 2000-08-18 | 2002-03-04 | University Of Massachusetts Medical Center | Trance regulation of chondrocyte differentiation |
AU9303001A (en) | 2000-09-22 | 2002-04-02 | Immunex Corp | Screening assays for agonists or antagonists of receptor activat or of nf-kb |
AU2002241859B2 (en) | 2001-01-10 | 2007-07-19 | St. Vincent's Institute Of Medical Research | sFRP and peptide motifs that interact with sFRP and methods of their use |
US7128911B2 (en) | 2001-01-19 | 2006-10-31 | Cytos Biotechnology Ag | Antigen arrays for treatment of bone disease |
MEP32608A (en) | 2001-06-26 | 2011-02-10 | Amgen Fremont Inc | Antibodies to opgl |
EP2192130A1 (de) | 2001-07-03 | 2010-06-02 | Genentech, Inc. | Humane DR4-Antikörper und deren Anwendungen |
JP2005508162A (ja) | 2001-10-02 | 2005-03-31 | ジェネンテック・インコーポレーテッド | Apo−2リガンド変異体とその使用法 |
US7842668B1 (en) | 2001-11-13 | 2010-11-30 | Genentech, Inc. | Apo-2 ligand/trail formulations |
DE60237841D1 (de) | 2001-11-13 | 2010-11-11 | Genentech Inc | Zusammensetzungen basierend auf APO2-Ligand/ TRAIL und ihre Verwendung |
US7741285B2 (en) | 2001-11-13 | 2010-06-22 | Genentech, Inc. | APO-2 ligand/trail formulations |
EP1494714A4 (de) | 2002-04-05 | 2008-03-05 | Amgen Inc | Humane anti-opgl-neutralisierende antikörper als selektive opgl-pfad-hemmer |
AU2011265413B2 (en) * | 2002-04-05 | 2014-04-10 | Amgen Inc. | Human Anti-OPGL Neutralizing Antibodies as Selective OPGL, Pathway Inhibitors |
US20060141561A1 (en) | 2002-06-24 | 2006-06-29 | Kelley Robert F | Apo-2 ligand/trail variants and uses thereof |
MXPA05006147A (es) | 2002-12-10 | 2005-08-26 | Schering Plough Ltd | Ligando del activador del receptor de nf-kb de canino, y metodos para preparar y usar el mismo. |
EP1773400A2 (de) | 2004-07-08 | 2007-04-18 | Amgen Inc. | Therapeutische peptide |
DK1774037T3 (da) | 2004-08-06 | 2011-08-15 | Genentech Inc | Analyser og fremgangsmåder, der anvender biomarkører |
BRPI0513665A (pt) | 2004-08-06 | 2008-05-13 | Genentech Inc | método de previsão da sensibilidade, métodos de indução da apoptose, método de tratamento de disfunção em mamìferos, método de previsão da sensibilidade e método de tratamento de cáncer do cólon ou colo-retal em mamìferos |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
US8029783B2 (en) | 2005-02-02 | 2011-10-04 | Genentech, Inc. | DR5 antibodies and articles of manufacture containing same |
ATE533058T1 (de) | 2005-08-16 | 2011-11-15 | Genentech Inc | Apoptosesensitivität gegenüber apo2l/trail mittels testen auf galnac-t14-expression in zellen/gewebe |
TW200736277A (en) | 2005-11-14 | 2007-10-01 | Amgen Inc | RANKL antibody-PTH/PTHrP chimeric molecules |
JP6088723B2 (ja) | 2005-11-23 | 2017-03-01 | ジェネンテック, インコーポレイテッド | B細胞アッセイに関する組成物及び方法。 |
JO3324B1 (ar) | 2006-04-21 | 2019-03-13 | Amgen Inc | مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية |
AU2007336751B2 (en) * | 2006-12-22 | 2013-08-01 | The Regents Of The University Of California | New fusion molecule based on novel TAA variant |
AU2008262490B2 (en) | 2007-05-22 | 2011-11-17 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
JP2008307007A (ja) | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
EP2565649B1 (de) * | 2007-06-20 | 2015-04-15 | Galapagos N.V. | Molekulare Targets und Verbindungen sowie Verfahren zu ihrer Identifizierung für die Behandlung von degenerativen Knochen- und Gelenkserkrankungen |
SG10201400329YA (en) * | 2008-05-02 | 2014-05-29 | Univ Kyoto | Method of nuclear reprogramming |
US8501178B2 (en) | 2008-11-25 | 2013-08-06 | Biogen Idec Ma Inc. | Use of DR6 and p75 antagonists to promote survival of cells of the nervous system |
EP2433644A1 (de) | 2010-09-22 | 2012-03-28 | IMBA-Institut für Molekulare Biotechnologie GmbH | Brustkrebstherapeutika |
EP2434285A1 (de) | 2010-09-22 | 2012-03-28 | IMBA-Institut für Molekulare Biotechnologie GmbH | Brustkrebsdiagnose |
WO2013130654A1 (en) | 2012-02-29 | 2013-09-06 | Coyote Pharmaceuticals, Inc. | Gga and gga derivatives, compositions thereof and methods for treating neurodegenerative diseases including paralysis including them |
US9119808B1 (en) | 2012-10-08 | 2015-09-01 | Coyote Pharmaceuticals, Inc. | Treating neurodegenerative diseases with GGA or a derivative thereof |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
WO2014144817A2 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Inhibitory polypeptides specific to wnt inhibitors |
EP3712166A1 (de) | 2013-09-05 | 2020-09-23 | Amgen Inc. | Fc-haltige moleküle mit vorhersagbaren, konsistenten und reproduzierbaren glycoformprofilen |
US10156562B2 (en) | 2014-05-16 | 2018-12-18 | Amgen Inc. | Assay for detecting Th1 and Th2 cell populations |
EP3574017A1 (de) | 2017-01-27 | 2019-12-04 | Kymab Limited | Anti-opg-antikörper |
MA47775A (fr) | 2017-03-14 | 2020-01-22 | Amgen Inc | Contrôle des glycoformes afucosylées totales d'anticorps produits en culture cellulaire |
CN111565725A (zh) | 2017-11-22 | 2020-08-21 | 生物运动有限公司 | 基于c-maf状态的乳腺癌的治疗性处理 |
IL313983A (en) | 2018-03-26 | 2024-08-01 | Amgen Inc | Fully fucose-free glycoforms of antibodies are produced in cell culture |
MX2022003461A (es) | 2019-09-26 | 2022-04-19 | Amgen Inc | Metodos de produccion de composiciones de anticuerpos. |
CN113621060B (zh) * | 2020-05-07 | 2023-07-04 | 浙江瑞硕生物技术有限公司 | 一种opg抗体对及其应用 |
WO2021247892A1 (en) | 2020-06-04 | 2021-12-09 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
KR20230087539A (ko) | 2020-10-15 | 2023-06-16 | 암젠 인크 | 항체 생산 방법에서의 상대적인 비결합 글리칸 |
CA3222409A1 (en) | 2021-06-07 | 2022-12-15 | Amgen Inc. | Using fucosidase to control afucosylation level of glycosylated proteins |
MX2024003852A (es) | 2021-10-05 | 2024-05-24 | Amgen Inc | Unión al receptor fc-gamma y contenido de glucanos. |
WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4710457A (en) | 1983-06-29 | 1987-12-01 | Sloan-Kettering Institute For Cancer Research | Monoclonal antibody for human hematopoietic glycoproteins and method |
US4710473A (en) | 1983-08-10 | 1987-12-01 | Amgen, Inc. | DNA plasmids |
US4959314A (en) | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
US6150090A (en) * | 1986-01-09 | 2000-11-21 | Massachusetts Institute Of Technology | Nuclear factors associated with transcriptional regulation |
US5846534A (en) | 1988-02-12 | 1998-12-08 | British Technology Group Limited | Antibodies to the antigen campath-1 |
JP3356775B2 (ja) | 1990-11-30 | 2002-12-16 | セルトリックス ファーマシューティカルズ, インコーポレイテッド | TGF―βとの共同的組合せによる骨修復のための骨形成タンパク質の使用 |
US5118667A (en) | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
CA2068389A1 (en) | 1991-05-13 | 1992-11-14 | Masahiko Sato | Method for inhibiting bone resorption |
MX9204303A (es) | 1991-07-23 | 1993-11-01 | Rhone Poulenc Rorer Int | Factor regulador del crecimiento de osteoclasto. |
IL99120A0 (en) | 1991-08-07 | 1992-07-15 | Yeda Res & Dev | Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them |
US5961974A (en) * | 1991-10-25 | 1999-10-05 | Immunex Corporation | Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same |
US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
JPH07509223A (ja) | 1992-04-30 | 1995-10-12 | アムジェン インコーポレイテッド | インターロイキン−1媒介疾患および腫瘍壊死因子媒介疾患の治療方法 |
US5585479A (en) | 1992-07-24 | 1996-12-17 | The United States Of America As Represented By The Secretary Of The Navy | Antisense oligonucleotides directed against human ELAM-I RNA |
US5578569A (en) | 1993-03-12 | 1996-11-26 | Tam; Cherk S. | Method of increasing bone growth |
US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
ES2157991T3 (es) | 1993-09-14 | 2001-09-01 | Merck & Co Inc | Cadn que codifica una nueva proteina humana, la tirosin-fosfatasa. |
US6268212B1 (en) | 1993-10-18 | 2001-07-31 | Amgen Inc. | Tissue specific transgene expression |
US5641747A (en) | 1994-07-25 | 1997-06-24 | Temple University-Of The Commonwealth System Of Higher Education | Treatment of osteopetrotic diseases |
ATE364614T1 (de) * | 1994-11-07 | 2007-07-15 | Human Genome Sciences Inc | Tumornekrose-faktor-gamma |
AU4440496A (en) | 1995-02-10 | 1996-08-22 | Smithkline Beecham Corporation | Use of src SH2 specific compounds to treat a bone resorption disease |
IL117175A (en) | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
US7094564B1 (en) | 1995-03-15 | 2006-08-22 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor |
US20030166097A1 (en) * | 1995-03-15 | 2003-09-04 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor |
WO1996028546A1 (en) | 1995-03-15 | 1996-09-19 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor |
AU5985996A (en) | 1995-06-07 | 1997-01-15 | Osteosa Inc. | Osteoclast growth regulatory factor |
US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
AU6090896A (en) | 1995-06-07 | 1997-01-15 | Osteosa Inc. | Osteoclast growth regulatory factor |
NZ311982A (en) * | 1995-06-29 | 1999-08-30 | Immunex Corp | Tnf related apoptosis inducing ligand (trail), a method for producing them and associated antibodies |
US6613544B1 (en) | 1995-12-22 | 2003-09-02 | Amgen Inc. | Osteoprotegerin |
US6369027B1 (en) | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
US6046048A (en) | 1996-01-09 | 2000-04-04 | Genetech, Inc. | Apo-2 ligand |
US5981220A (en) * | 1996-03-27 | 1999-11-09 | Human Genome Sciences, Inc. | Epidermal differentiation factor |
TW555765B (en) * | 1996-07-09 | 2003-10-01 | Amgen Inc | Low molecular weight soluble tumor necrosis factor type-I and type-II proteins |
JPH1057071A (ja) | 1996-08-19 | 1998-03-03 | Snow Brand Milk Prod Co Ltd | 新規dna及びそれを用いた蛋白質の製造方法 |
EP1114864B9 (de) * | 1996-12-13 | 2013-05-08 | Schering Corporation | Oberflächenantigene aus Säugern |
EP0951546A2 (de) | 1996-12-20 | 1999-10-27 | The Board Of Regents, The University Of Texas System | Zusammensetzungen und verfahren zur verwendung von osteoklasthemmenden faktoren |
FR2757507B1 (fr) | 1996-12-20 | 1999-01-29 | Inst Francais Du Petrole | Procede de separation de paraxylene comprenant une adsorption avec injection d'eau et une cristallisation |
JP4138013B2 (ja) * | 1996-12-23 | 2008-08-20 | イミュネックス・コーポレーション | Tnfスーパーファミリーのメンバーであるnf−kappa bの受容体アクティベーターに対するリガンド |
US6271349B1 (en) | 1996-12-23 | 2001-08-07 | Immunex Corporation | Receptor activator of NF-κB |
HU229476B1 (en) * | 1997-04-15 | 2014-01-28 | Daiichi Sankyo Company | Antibodies against obm |
US5843678A (en) * | 1997-04-16 | 1998-12-01 | Amgen Inc. | Osteoprotegerin binding proteins |
US6316408B1 (en) | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
ATE363533T1 (de) | 1997-04-16 | 2007-06-15 | Amgen Inc | Osteoprotegerin bindende proteine und rezeptoren |
CA2229449A1 (en) * | 1997-04-25 | 1998-10-25 | Takeda Chemical Industries, Ltd. | Novel receptor protein and its use |
WO1998049305A1 (en) | 1997-05-01 | 1998-11-05 | Amgen Inc. | Chimeric opg polypeptides |
AU7705098A (en) | 1997-05-29 | 1998-12-30 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like protein 8 |
US6087555A (en) | 1997-10-15 | 2000-07-11 | Amgen Inc. | Mice lacking expression of osteoprotegerin |
US6790823B1 (en) | 1998-04-23 | 2004-09-14 | Amgen Inc. | Compositions and methods for the prevention and treatment of cardiovascular diseases |
EP1076699B1 (de) * | 1998-05-14 | 2008-10-29 | Immunex Corporation | Verfahren zur hemmung der wirkung der osteoklasten |
WO2000015807A1 (en) * | 1998-09-15 | 2000-03-23 | M & E Biotech A/S | Method for down-regulating osteoprotegerin ligand activity |
AU6078500A (en) | 1999-07-09 | 2001-01-30 | Amgen, Inc. | Combination therapy for conditions leading to bone loss |
CA2349406C (en) | 1999-09-03 | 2011-01-11 | Amgen Inc. | Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer |
US20030144187A1 (en) | 1999-09-03 | 2003-07-31 | Colin R. Dunstan | Opg fusion protein compositions and methods |
US20030103978A1 (en) * | 2000-02-23 | 2003-06-05 | Amgen Inc. | Selective binding agents of osteoprotegerin binding protein |
DK2105449T3 (da) | 2000-02-23 | 2019-10-07 | Amgen Inc | Antagonistiske selektive bindemidler af osteoprotegerinbindende protein |
AU2001286586A1 (en) | 2000-08-18 | 2002-03-04 | University Of Massachusetts Medical Center | Trance regulation of chondrocyte differentiation |
AU9303001A (en) * | 2000-09-22 | 2002-04-02 | Immunex Corp | Screening assays for agonists or antagonists of receptor activat or of nf-kb |
JP2004536056A (ja) | 2001-05-17 | 2004-12-02 | イミュネックス・コーポレーション | Rankアンタゴニストの療法使用 |
CA2449658A1 (en) * | 2001-06-06 | 2002-12-12 | Immunex Corporation | Use of rank antagonists to treat cancer |
MEP32608A (en) | 2001-06-26 | 2011-02-10 | Amgen Fremont Inc | Antibodies to opgl |
US6753755B2 (en) * | 2001-06-28 | 2004-06-22 | Safer Home, Inc. | Electrical safety connector fuse |
US7084257B2 (en) * | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
US6592001B2 (en) * | 2001-12-18 | 2003-07-15 | Kimberly-Clark Worldwide | Dispenser for sheet material containing a dispensing port incrementally variable within a range |
EP1494714A4 (de) | 2002-04-05 | 2008-03-05 | Amgen Inc | Humane anti-opgl-neutralisierende antikörper als selektive opgl-pfad-hemmer |
US7706431B2 (en) * | 2005-06-30 | 2010-04-27 | Nokia Corporation | System and method for providing optimized receiver architectures for combined pilot and data signal tracking |
-
1998
- 1998-04-15 AT AT98918244T patent/ATE363533T1/de active
- 1998-04-15 CA CA2285746A patent/CA2285746C/en not_active Expired - Lifetime
- 1998-04-15 CZ CZ0359899A patent/CZ302262B6/cs not_active IP Right Cessation
- 1998-04-15 SI SI9830889T patent/SI0975754T2/sl unknown
- 1998-04-15 DE DE69837845.8T patent/DE69837845T3/de not_active Expired - Lifetime
- 1998-04-15 ES ES98918244.9T patent/ES2284203T5/es not_active Expired - Lifetime
- 1998-04-15 NZ NZ500253A patent/NZ500253A/xx not_active IP Right Cessation
- 1998-04-15 BR BR9808545-0A patent/BR9808545A/pt not_active Application Discontinuation
- 1998-04-15 WO PCT/US1998/007584 patent/WO1998046751A1/en active IP Right Grant
- 1998-04-15 CN CN98806073A patent/CN1264427A/zh active Pending
- 1998-04-15 AU AU71205/98A patent/AU743257B2/en not_active Ceased
- 1998-04-15 EE EEP199900611A patent/EE05496B1/xx unknown
- 1998-04-15 HU HU0001400A patent/HU230547B1/hu unknown
- 1998-04-15 JP JP54425798A patent/JP2001526532A/ja not_active Withdrawn
- 1998-04-15 EP EP06015956A patent/EP1717315A3/de not_active Withdrawn
- 1998-04-15 IL IL13230498A patent/IL132304A0/xx unknown
- 1998-04-15 SK SK1419-99A patent/SK288559B6/sk active Protection Beyond IP Right Term
- 1998-04-15 EA EA199900939A patent/EA003636B1/ru not_active IP Right Cessation
- 1998-04-15 TR TR1999/02512T patent/TR199902512T2/xx unknown
- 1998-04-15 PL PL98336311A patent/PL190092B1/pl unknown
- 1998-04-15 EP EP98918244.9A patent/EP0975754B2/de not_active Expired - Lifetime
- 1998-04-15 RO ROA201200577A patent/RO128635A2/ro unknown
- 1998-04-15 ID IDW991225A patent/ID23855A/id unknown
- 1998-04-15 DK DK98918244.9T patent/DK0975754T4/en active
- 1998-04-16 TW TW087105837A patent/TW589376B/zh not_active IP Right Cessation
-
1999
- 1999-10-15 NO NO19995044A patent/NO325175B1/no not_active IP Right Cessation
- 1999-10-21 BG BG103824A patent/BG65242B1/bg unknown
-
2000
- 2000-02-25 HK HK00101154A patent/HK1022330A1/xx not_active IP Right Cessation
-
2001
- 2001-11-30 AU AU95234/01A patent/AU779461C/en not_active Expired
-
2005
- 2005-04-27 AU AU2005201799A patent/AU2005201799B2/en not_active Expired
-
2006
- 2006-01-19 US US11/336,067 patent/US7923008B2/en not_active Expired - Fee Related
-
2007
- 2007-09-04 JP JP2007228804A patent/JP5001758B2/ja not_active Expired - Lifetime
-
2008
- 2008-06-05 AU AU2008202516A patent/AU2008202516A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69837845D1 (de) | Osteoprotegerin bindende proteine und rezeptoren | |
Kasugai et al. | Differential regulation of the 55 and 44 kDa forms of secreted phosphoprotein 1 (SPP-1, osteopontin) in normal and transformed rat bone cells by osteotropic hormones, growth factors and a tumor promoter | |
Marchbank et al. | Dimerization of human pS2 (TFF1) plays a key role in its protective/healing effects | |
FI961251A0 (fi) | Ihmisten metabotrooppiset glutamaattireseptorialatyypit(HMR4, HMR6, HMR7)ja niihin liittyvät DNA-yhdisteet | |
EP2325316B8 (de) | Neues Hämopoietin Receptorprotein, NR10 | |
DE69406423D1 (de) | Methode zum überbringen von agenzien an zielzellen | |
DE69535641D1 (de) | Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen | |
BRPI9809391B8 (pt) | processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica | |
BR9814335A (pt) | Proteìna, exceto as existentes ao natural, polinucleotìdeo substancialmente puro, anticorpo elaborado por um processo que compreende a etapa de injetar uma preparação farmaceuticamente aceitável, vetor para expressar o drr-1 de rato, vetor, célula hospedeira drr-1 de rato, drr-1 de ser humano, drr-2 de ser humano, drr-3 de ser humano, drr-4 de ser humano, drr-5 de ser humano, drr-6 de ser humano recombinantes, e, processo para ensaiar um composto de teste quanto à sua capacidade para ligar-se a ou para ativar um receptor especìfico de gânglios da raiz dorsal ligado à proteìna g (drr) | |
LU91759I2 (fr) | Denosumab et ses dérivés pharmaceutique acceptables (PROLIA®) | |
EA200300381A1 (ru) | Нуклеиновые кислоты и полипептиды нового рецептора | |
BR9811861A (pt) | Polipeptìdeos de fatores de crescimento ligantes de heparina (fclh) | |
BR9508467A (pt) | Composição de matéria peptídeo de ligação de receptor de somatostatina composição farmacéutica e processo para realizar uma cirurgia guiada por radiosótopos ou um procedimento de radiodiagnóstico ou radioterapéutico e para aliviar uma doença relacionada com somatostetina em um animal | |
DE59814354D1 (de) | Zellvolumenregulierte humane Kinase h-sgk | |
BR0013043A (pt) | Proteìna isolada, anticorpo isolado, composição, método de regulação de reação imunológica em animais, método de tratamento de câncer em animais, molécula de ácido nucleico isolado, molécula de ácido nucleico recombinante, célula recombinante e vìrus recombinante | |
DK0877803T3 (da) | OB-proteinreceptor og relaterede sammensætninger og fremgangsmåder | |
WO1997007135A3 (en) | Binding of osteogenic protein-i (op-1) and analogs thereof to the cell surface receptor alk-1 and analogs thereof | |
ATE407944T1 (de) | Mit trp-proteinen verwandtes protein mtr1 und dieses codierende dna-sequenz | |
WO1999019480A3 (en) | Human receptor proteins; related reagents and methods | |
GEP20002244B (en) | Osteoprotegerin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 0975754 Country of ref document: EP |